Citation

Gibbs HM, Price D, Delgado PL, Clothier JL, Caceda R. Int. J. Psychiatry Med. 2020; 55(6): 387-396.

Copyright

(Copyright © 2020, SAGE Publishing)

DOI

10.1177/0091217420913396

PMID

32216493

Abstract

OBJECTIVE: Chronic pain is frequently comorbid with opioid abuse and severe depression, a combination that greatly compounds suicide risk. In addition to the therapeutic value of buprenorphine in addiction and analgesia, growing evidence suggests potential use as an antidepressant. Data supporting buprenorphine antisuicidal properties are scarce. We aim to contribute to the discussion of buprenorphine antisuicidal potential in patients with significant psychiatric and medical comorbidity.
METHODS: We performed a chart review of suicidal adult depressed patients with comorbid chronic pain and opioid use disorder who received off-label buprenorphine in outpatient and inpatient settings in a university hospital between 2013 and 2016.
RESULTS: Four of the patients had an early positive response. However, only three continue to adhere to treatment for six months or longer.
CONCLUSIONS: More severe opioid use disorder seems to more negatively influence clinical outcome, independently of cluster b personality traits. Identification of patients who could benefit from buprenorphine will require further studies.

Language: en

Keywords

Humans; Adult; Female; Male; Middle Aged; suicide; Retrospective Studies; Suicidal Ideation; depression; personality; Antidepressive Agents; pain; Analgesics, Opioid; Buprenorphine; Depressive Disorder; buprenorphine; Chronic Pain; Pain Management